Back to Authors

Derian, Armen

Mayo Clinic

University of Miami

Citations 2

Accuracy of ultrasound-guided versus palpation-based carpometacarpal joint injections: A randomized pilot study in cadavers
Derian, Armen, Abi-Aad, Karl R., Vasquez‐Duarte, Ricardo J., Johnson‐Greene, Douglas, Abi-Aad, Karl, Amundson, Julia R. , Johnson‐Greene, Doug

Ultrasound | July 26, 2018 | Volume: 26 | Issue: 4 | Pages: 245-250

10.1177/1742271x18789711 Get It

Objective To determine the accuracy of ultrasound guidance compared to palpation in performing carpometacarpal joint injections in cadavers. Design In all, 36 carpometacarpal joints were randomized to either ultrasound-guided or palpation-based injections, with 1 cc of blue latex solution injected into each joint. The specimens were then dissected and the distribution of the latex was assessed by two independent, blinded raters. Injection accuracy was evaluated on a four-point quartile rating scale of 1–4, corresponding to the amount of the latex solution within the joint (1 = 0–25%, 2 = 26–50%, 3 = 51–75%, 4 = 76–100%). Inter-rater reliability was a secondary measure. Results The mean rating of accuracy was 2.1 for both palpation-based and ultrasound-guided injections. There was no statistically significant difference in accuracy between the two injectors. Chi-square analysis testing differences in accuracy for the two conditions was not statistically significant. The Cronbach’s alpha for rater 2 was 0.74, which represents an acceptable level of reliability. A Friedman’s Chi-square for the two raters was 2.3 ( p = 0.13), indicating no significant difference between raters. Conclusion Ultrasound guidance did not improve the accuracy of carpometacarpal joint injections in cadavers. However, the high inter-rater reliability attests to the value of the novel assessment scale.
Short-Term Outcomes in Treatment of Knee Osteoarthritis With 4 Bone Marrow Concentrate Injections
Shaw, Brent , Darrow, Marc, Derian, Armen

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders | June 18, 2018 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1179544118781080 Get It

Background: Preliminary research suggests that bone marrow concentrate (BMC), which contains mesenchymal stem cells and platelets, is a promising treatment for knee osteoarthritis. The aim of this study was to build on this preliminary research by reporting the short-term progress of 15 patients (20 knees) with knee osteoarthritis through 4 BMC treatments. Methods: Patients underwent four sequential BMC treatments with mean injection times of 13.80 days after the first treatment, 21.40 days after the second treatment, and 33.50 days after the third treatment. The last follow-up was conducted a mean 86 days after the first treatment. Baseline and posttreatment outcomes of resting pain, active pain, lower functionality scale, and overall improvement percentage were compared after each treatment. Results: Patients experienced statistically significant improvements in active pain and functionality score after the first treatment. Additionally, patients experienced a mean decrease in resting pain after the first treatment, yet outcomes were not statistically significant until after the second treatment. On average, patients experienced an 84.31% decrease in resting pain, a 61.95% decrease in active pain, and a 55.68% increase in functionality score at the final follow-up. Patients also reported a mean 67% total overall improvement at study conclusion. Outcomes at the final follow-up after the fourth treatment were statistically significant compared to outcomes at baseline, after first treatment, after second treatment, and after third treatment. Conclusions: These results are promising, and additional research with a larger sample size and longer follow-up is needed to further examine the treatment effectiveness of multiple BMC injections for knee osteoarthritis.